POETYK PSO‐3, a 52‐week, double‐blind, phase 3 study, evaluated the efficacy and safety of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in adult patients with moderate to severe plaque psoriasis in mainland China, Taiwan, and South Korea. This evidence concerns the gene TYK2 and psoriasis vulgaris.